Carcinoid tumors of the lung and multimodal therapy

Thorac Cardiovasc Surg. 2005 Jun;53(3):168-72. doi: 10.1055/s-2005-837539.

Abstract

Aim: To report our experience with bronchial carcinoids.

Methods: From January 1990 to March 2003 we treated 42 such patients, 30 females and 12 males. All patients underwent preoperative total body computed tomography (CT), total body In-111 octreotide scintigraphy, and SPECT of the thorax, with evaluation of serum levels of CEA, CgA, NSE, and urinary 5-HIAA. Diagnosis was obtained in 28 patients with fibre-optic bronchoscopy and in 14 patients with CT-guided trans-thoracic needle biopsy.

Results: There were 26 typical and 16 atypical carcinoids. 30 lobectomies, 5 bilobectomies, 6 wedge resections, and 1 pneumonectomy were carried out. The 3-year and the 5-year survival rates in the typical and atypical carcinoid groups were 100 % and 96 % vs. 81 % and 68 %, respectively (p < 0.001).

Conclusions: Long-term survival is based on histological completeness of surgical treatment. Octreotide scintigraphy and SPECT document N (1) and N (2) precisely.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents, Hormonal
  • Bronchoscopy
  • Carcinoid Tumor / blood
  • Carcinoid Tumor / diagnosis
  • Carcinoid Tumor / metabolism
  • Carcinoid Tumor / mortality
  • Carcinoid Tumor / surgery*
  • Chromogranin A
  • Chromogranins / metabolism
  • Combined Modality Therapy
  • Female
  • Humans
  • Immunohistochemistry
  • Lung Neoplasms / blood
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / mortality
  • Lung Neoplasms / surgery*
  • Male
  • Middle Aged
  • Octreotide
  • Pneumonectomy*
  • Retrospective Studies
  • Synaptophysin / metabolism
  • Tomography, Emission-Computed, Single-Photon

Substances

  • Antineoplastic Agents, Hormonal
  • Chromogranin A
  • Chromogranins
  • Synaptophysin
  • Octreotide